Home
overview

SMi is proud to present the return of their 6th annual Cancer Vaccines conference to London in September 2017. The use of therapeutic cancer vaccines in combination with other therapies remains the most effective method of cancer treatment available. With diversification of cancer vaccines propelling growth and innovation in the cancer vaccines industry, approaches to combatting cancer and enhancing vaccine efficacy are developing and improving year on year.

With particular focus on autologous tumour cell immunotherapy, combinatorial approaches including immune checkpoint inhibitors and IDO inhibitors and clinical trials, SMi’s 6th annual Cancer Vaccines conference will provide the perfect platform to highlight emerging strategies in cancer vaccines, and overcome the challenges facing development of successful vaccines for what is a competitive and important market.

This event will bring together industry leaders to share ideas and experience of developing successful cancer vaccines. 16+ industry led presentations and focus on the latest advances in personalised cancer treatments make this a leading event for the cancer vaccines industry.

• Exploring personalising cancer vaccines, characterising and applying the outside in approach in cancer vaccine development
• Maximising the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors
• Benefit from in depth case study examples showcasing peptide, neoantigen and MHC based vaccine development
• Assessing the emerging pipeline of preclinical data for preventative cancer vaccines
 

Directors, senior scientists, project leaders, research directors of:

Immuno-oncology, vaccine development, oncology, molecular medicine, immunobiology

4-Antibody AG; Abzena; Agenus; Amal Therapeutics; Anticancer Fund; Antwerp University; BioNTech AG; Boehringer Ingelheim Pharma GmbH & Co. KG; Cancer Research UK; ccit-denmark; Center into DiseasesFor Public Health Research; Exicure Inc.; Genentech, Inc.; Hadassah Medical School; Health Protection Scotland; ImmunoCellular Therapeutics Ltd; IO Biotech; IP & Science; Kings College London; Merck Research Laboratories; Midatech Pharma PLC; MilliporeSigma (Merck, KGaA); MSD; Northwest Biotherapeutics; Oxford BioMedica (U K) Limited; ProImmune Ltd.; Ross Univ Sch Of Med; Shionogi; SKAN AG; Talentmark Limited; The Life Sciences Division; Translational Oncology (TRON); UCL; Woodford Investment Management;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Michael Hanna

Michael Hanna, CEO, Vaccinogen

9:10 Strategies for designing and developing successful cancer vaccines

Michael Hanna

Michael Hanna, CEO, Vaccinogen

• The paradoxes of tumour genomic heterogeneity for cancer vaccines and other personalised cancer treatments
• The “outside in” versus the “inside out approach to active immunotherapy of cancer
• Important host tumour interactions: antigen competition driven immune editing
• The limits of tumour stage for optimised active immunotherapy clinical benefit
• The potential of the host tumour interactions in limiting and/or restricting genomic diversity of tumours and providing a pathway to truly functional neoantigens

9:50 Generation of fully personalised cancer vaccines with a potent, cost-effective and robust technology

Agnete Fredriksen

Agnete Fredriksen, CSO, Vaccibody AS
View Bio

• How to increase potency of neoantigen-based cancer vaccines without increasing manufacturing complexity
• Do we need to optimize neoepitope selection for each therapeutic modality?

10:30 Morning Coffee

11:00 Combined adjuvants for synergistic activation of cellular immunity (CASAC)

Farzin Farzaneh

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

• Induction of therapeutically effective cellular immunity against cancer associated antigens, for immune therapy of cancer, remains a major challenge
• Given the age associated prevalence of cancer, therapeutic vaccination needs to be effective in conditions of immune senescence
• Therapeutic outcome in response to vaccination will also be dependent on the effective blockade of tumour induced immune suppression, tumour microenvironment, and adequate access of the effector cells to the target cells and tissues
• The development of a platform for screening based identification of combinations of immune regulators, enabling the induction of very effective stimulation of antigen specific cellular immunity will be described
• The path to the clinical evaluation of a number of strategies for the vaccination induced cellular immunity will be discussed

11:40 DCVax®: Novel personalised immune therapies for solid tumours

Linda Powers

Linda Powers, CEO, Northwest Biotherapeutics Inc

• DCVax® is a fully personalised precision medicine, tailored to the individual patient and their tumour
• DCVax® is designed to mobilise many active agents of the immune system to hit many targets on the cancer, unlike conventional cancer drugs and some other immune therapies, which generally use a single active agent to hit a single target on the cancer
• A full course of DCVax® doses can be manufactured in a single batch within about a week, and can be stored frozen until needed (including for years)

12:20 Networking Lunch

13:30 Therapeutic potential of cancer vaccines and immune checkpoint inhibitors

Kandeepan Ganeshalingam

Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited
View Bio

• Rise of immune checkpoint inhibitors in the therapeutic development for cancer
• Priming of patients with cancer vaccines for the treatments with immune checkpoint inhibitors
• Synergistic function of  the combination of cancer vaccines and  immune checkpoint inhibitors, like the aPD1 Pembrolizumab in the induction of more effective antitumor immune responses

14:10 Activation of the immune system in combination with checkpoint inhibitors

David Giljohann

David Giljohann, CEO, Exicure Inc.
View Bio

• Spherical Nucleic Acid (SNA™) are nanoscale, spherical arrangements of densely packed and radially oriented nucleic acids
• Localisation to endosome permits large numbers of SNAs to be delivered with low toxicity
• By activating innate immune cells, SNAs enhance the function and secretion of cytokines
• AST-008 is a TLR9 agonist oligonucleotide in SNA format which demonstrates greater delivery to primary cells and more potent TLR9 activation in cell-based assays
• AST-008 has been evaluated in numerous solid and liquid tumour models, including breast, colon, bladder, melanoma and lymphoma
• Combining AST-008 with a checkpoint inhibitor (PD-1) results in a profound impact on tumour growth and survival
• An update on clinical progress will be provided

14:50 Afternoon Tea

15:20 Cancer immunotherapy combination development strategies

Fatema Legrand

Fatema Legrand, Senior Clinical Scientist , Genentech
View Bio

• A DNA vaccine in combination with an immunomodulatory all-trans retinoic acid (ATRA) eliciting specific immune responses in myeloid malignancies with a reduction of tumour burden and antibody response
• Real time imaging reveals effector cells inducing cell death of target cells
• Depletion experiments show that the protective effects are immune mediated
• Nf-kB signalling molecules upregulated

16:00 Cell wars: the immune system fights back

Rose-Ann Padua

Rose-Ann Padua, Director of Research, INSERM

• A DNA vaccine in combination with an immunomodulatory all-trans retinoic acid (ATRA) eliciting specific immune responses in myeloid malignancies with a reduction of tumour burden and antibody response
• Real time imaging reveals effector cells inducing cell death of target cells
• Depletion experiments show that the protective effects are immune mediated
• Nf-kB signalling molecules upregulated

16:40 Panel discussion: Can cancer vaccines be 100% effective?

• How do we define ‘successful treatment’?
           o Patient survival?
           o Response rate to treatment?
• Single vs. combination therapies; what are the implications of a vaccine no longer being a replacement technology but a companion technology?
• Discussing emerging and new approaches to cancer vaccine development
           o Towards preventative vaccines
           o Progress made in increasing cancer vaccine efficacy

Michael Hanna

Michael Hanna, CEO, Vaccinogen

Kandeepan Ganeshalingam

Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited
View Bio

Adnane  Achour

Adnane Achour, Structural and Biophysical Immunobiology, Karolinska Institutet
View Bio

17:20 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Michael Hanna

Michael Hanna, CEO, Vaccinogen

9:10 Enhanced cancer vaccine effectiveness with NKTR-214, a CD122-biased cytokine

Steve Doberstein

Steve Doberstein, Chief Scientific Officer, Nektar Therapeutics Inc
View Bio

• NKTR-214 biases signalling through the IL-2 receptor pathway to generate profound effector T-cell responses while reducing regulatory T-cell activity in tumours
• Combination dosing of NKTR-214 dramatically enhances activity of several tumour vaccine modalities in mouse models
• The unique profile of T-cell activity generated by NKTR-214 may enable the next generation of tumour vaccines

9:50 Vaccines with phosphopeptides

Zahra Jawad

Zahra Jawad, Group Leader in Discovery Technology, Agenus

• Phosphopeptides as an alternative to peptides for vaccinations
• New data showing the immunogenicity profile of phosphopeptides
• Pre-clinical models of anti-tumour efficacy

10:30 Morning Coffee

11:00 Structural and biophysical bases for the induction of efficient CTL responses against cancer-associated neoantigens

Adnane  Achour

Adnane Achour, Structural and Biophysical Immunobiology, Karolinska Institutet
View Bio

11:40 In vitro validation of potential neo-epitopes by MHC based reagents

Sune Justesen

Sune Justesen, CSO, Immunitrack Aps
View Bio

• Affinity vs. Stability based peptide MHC assays, implications on current in silico tools 
• What does a neo-epitope look like from the MHC perspective?
• High throughput MHC tetramer production to support personalized cancer vaccination trials

12:20 Networking Lunch

13:10 Targeting the tumor microenvironment with vaccine-activated anti-regulatory T cells

Mads Hald Andersen

Mads Hald Andersen, Vice-Director, Professor, Co-Founder, ccit-denmark
View Bio

• Describe the discovery of self-reactive, pro-inflammatory T cells—termed anti-regulatory T cells (anti-Tregs) -  effector T cells that specifically  target immune-suppressive cells (including cancer cells)
• Providing examples of antigen-specific anti-Tregs
• Discussing their possible roles in immune homeostasis
• Current clinical vaccination trials and potential future clinical applications

14:10 Individualised mRNA cancer immunotherapy

Ludwig Heesen

Ludwig Heesen, Project Manager, BioNTech AG
View Bio

• Development of nanoparticle formulation for systemic RNA delivery
• Liposome formulated RNAs (RNA-Lipoplex)
• Personalised cancer vaccine (IVAC® platform)

14:50 Afternoon Tea

15:20 Immune modulation as an essential tool for cancer vaccines

Angus Dalgleish

Angus Dalgleish, Research Director, Onyvax Ltd.

• Cancer vaccines require an optimal adjuvant
• The ‘work’ better with correct immune modulation
• Immune modulation can be achieved with IMiDs (Thalidomide analogues) or low dose chemotherapy
• Some agents, such as IMM-101 were developed as cancer vaccines but are actually very powerful immune modulators

16:00 In vitro assays to accelerate cancer therapy development

Sofie Pattijn

Sofie Pattijn, Chief Technology Officer, ImmunXperts

• In vitro assays using primary human cells are a useful tool to screen the functional properties of lead molecules/therapies and to document the mechanism of action
• Development of potency assays
• Functional screening of immune checkpoint inhibitors

16:40 Effect of adjuvant/delivery system(s) on vaccine efficacy, two examples PAP/HAGE vaccines

Stephanie McArdle

Stephanie McArdle, Senior Research Scientist, Nottingham Trent University
View Bio

• How a single amino-acid can change the immunogenicity of your vaccine
• How different adjuvants affect differently the immunogenicity of vaccine
• How different delivery systems also affect differently the immunogenicity of vaccine

17:20 Chairman’s Closing Remarks and Close of Day Two

+

FEATURED SPEAKERS

Agnete Fredriksen

Agnete Fredriksen

CSO, Vaccibody AS
David Giljohann

David Giljohann

CEO, Exicure Inc.
Kandeepan Ganeshalingam

Kandeepan Ganeshalingam

Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited
Ludwig Heesen

Ludwig Heesen

Project Manager, BioNTech AG
Mads Hald Andersen

Mads Hald Andersen

Vice-Director, Professor, Co-Founder, ccit-denmark
Michael Hanna

Michael Hanna

CEO, Vaccinogen
Sofie Pattijn

Sofie Pattijn

Chief Technology Officer, ImmunXperts

Adnane Achour

Structural and Biophysical Immunobiology, Karolinska Institutet
Adnane  Achour

Prof. Achour received his BSc degree in Biophysical Chemistry and Mathematics, Umeå University, Sweden (1990), then MSc degree from the Royal Institute of Technology in Chemical Engineering (1994). Prof. Achour defended his PhD thesis in molecular immunology within the research group of Prof. Klas Kärre at the Karolinska Institute, Stockholm, Sweden (2001), followed by post-doctoral studies in the research group of Prof. Hans-Gustaf Ljunggren at the Karolinska Institute until 2003. He is one of the founders of the Center for Infectious Medicine (CIM) at the Karolinska University Hospital in Huddinge and a principal Investigator since 2003. Additionally, he has been the director of the national Swedish platform for mass-cytometry as well as director for the flow cytometry platform within SciLifeLab from 2012 to 2017. Adnane Achour is Professor in Molecular Immunology at the Department of Medicine in Solna and at the Science for Life Laboratories (SciLifeLab).
 

Adnane Achour has expertise in both structural biology and immunology. The research group uses X-ray crystallography and Small Angle X-ray Scattering (SAXS) to study receptor-ligand interactions between T or NK cell receptors and Major Histocompatibility Complex (MHC) molecules, as well as bacterial adhesins and virulence-associated molecules. All the studies are complemented by a wide array of immunological assays as well as an extensive amount of biochemical techniques, including e.g. surface plasmon resonance, isothermal titration calorimetry, microscale thermophoresis and circular dichroism. By understanding the structural details of proteins, it is possible to probe their function and potentially design modified ligands that can modulate lymphocyte function and activity in a variety of diseases including cancer, viral infections and autoimmunity.

Agnete Fredriksen

CSO, Vaccibody AS
Agnete Fredriksen

Agnete B. Fredriksen is Founder and Chief Scientific Officer of Vaccibody AS. She holds a M.Sc., Ph.D. from Institute of Immunology, University of Oslo, Rikshospitalet in Norway where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies. She has co-authored a range of scientific papers and is inventor on several patents with a focus on vaccine development and immunotherapy. She is in charge of preclinical and clinical development of Vaccibody’s cancer vaccine programs.

Angus Dalgleish

Research Director, Onyvax Ltd.
Angus Dalgleish

David Giljohann

CEO, Exicure Inc.
David Giljohann

Dr. Giljohann has served as Exicure’s Chief Executive Officer since November 2013 and been on its board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was Exicure’s Chief Operating Officer and its founding scientist in 2011. From 2011 to June 2012, Dr. Giljohann served as the company’s principal scientist. Prior to that, Dr. Giljohann was the founding scientist of AuraSense, LLC in 2009. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.

Farzin Farzaneh

Professor of Molecular Medicine, Kings College London
Farzin Farzaneh

Fatema Legrand

Senior Clinical Scientist , Genentech
Fatema Legrand

Fatema Legrand is a senior clinical scientist in the cancer immunotherapy development program at Genentech/Roche where she has led the global filing of atezolizumab, a PD-L1 inhibitor, in metastatic urothelial carcinoma. She holds a master’s degree in biological sciences from Harvard University and received her PhD in Comparative Pathology with a designated emphasis in biotechnology from UC Davis. She completed her postdoctoral research at UCSF/Gladstone Institute of Virology & Immunology, studying the development of the infant immune system in the setting of pediatric HIV infection. Prior to joining Genentech/Roche in 2013, Fatema directed the translational science program for early and late phase poxvirus based cancer immunotherapy candidates at BN ImmunoTherapeutics (a subsidiary of Bavarian-Nordic) from 2006-2013. She has co-authored several manuscripts on vaccine development and is a co-inventor of and holds a patent for the prostate cancer vaccine, MVA-BN-PRO.

Kandeepan Ganeshalingam

Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited
Kandeepan Ganeshalingam

Dr. Kandeepan Ganeshalingam received his Medical Degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine, University of London. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK.
Following a 10 year career as a physician in the National Health Service Hospitals, UK, he joined the Oncology product development team at Roche in 2007. In this role he played a significant role in product development with several successful submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the Global Head of Medical and Clinical Drug Safety, where he played a leadership role in clinical development, regulatory submissions and safety risk management. In 2012, he returned to Roche Product Development Medical Affairs as Senior Medical Director, in immunology and was subsequently promoted to Group Medical Director in Oncology, where he led the Global Medical team responsible for multiple Haematology/Oncology products. In this role he was instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies.
In 2016, he joined Merck Sharp Dohme as the Executive Director, Oncology Therapeutic Area Head, European Clinical Development.

Linda Powers

CEO, Northwest Biotherapeutics Inc
Linda Powers

Ludwig Heesen

Project Manager, BioNTech AG
Ludwig Heesen

Ludwig Heesen studied Biology at the University of Würzburg, Germany from September 2002 to March 2008, after which he obtained his PhD in Genetics, and Post-Doc at the University Hospital Cologne and Institute of Reconstructive Neurobiology, University of Bonn, ending in 2015. Since April 2016 Dr. Heesen has been at BioNTech, where he now works as a Clinical Project Manager.

Mads Hald Andersen

Vice-Director, Professor, Co-Founder, ccit-denmark
Mads Hald Andersen

Mads Hald Andersen is vice-director at Center for Cancer Immune Therapy at Copenhagen University Hospital at Herlev as well as professor at Department of Immunology and Microbiology at Copenhagen University. In 2001 he gained his PhD from the Danish Cancer Society, Copenhagen, Denmark, and the Department of Dermatology, Würzburg University, Germany. The same year he co-founded the Tumor Immunology Group at the Danish Cancer Society. He obtained his DScTech in 2006, the same year as he co-founded the Center for Cancer Immune Therapy at Copenhagan University Hospital at Herlev. In 2015 he additionally achieved the DMSc degree from Copenhagen University. Professor Andersen has considerable pharmaceutical experience, and has founded several biotech companies including Survac, Rhovac and most recently IO Biotech Aps. He has been honored with several awards during his career including The Lundbeck Foundation research prize (2012), the Danish Cancer Society Research Award (2006) and the Hallas-Møller Stipend from the Novo Nordisk foundation (2007). He has an extensive publication record, authoring over 150 publications in peer reviewed journals, more than 15 patents as well as several book chapters. His research has been focusing on the characterization of the natural immune responses towards malignant cells. He has identified a number of different T-cell antigens including survivin, the Bcl-2 family and RhoC. Recently, he described circulating T cells that specifically target normal, self-proteins, e.g., IDO, TDO, PD-L1 and Foxp3, expressed by regulatory immune cells and defined these as anti-Tregs.

Michael Hanna

CEO, Vaccinogen
Michael Hanna

Rose-Ann Padua

Director of Research, INSERM
Rose-Ann Padua

Sofie Pattijn

Chief Technology Officer, ImmunXperts
Sofie Pattijn

Stephanie McArdle

Senior Research Scientist, Nottingham Trent University
Stephanie McArdle

Stephanie McArdle is at the head of T-cell vaccine immunotherapy, which is mainly focused on the validation of novel immunotherapeutic targets as well as immune-phenotyping patient’s blood. She is particularly interested in HAGE and PAP antigens as targets and/or biomarkers for cancers. She is also very interested in understanding the role of stress and diet supplement on vaccine outcome. Stephanie supervises many PhD students as director of studies as well as second supervisor and MSc/MRes students. She has recently successfully completed projects contracted by two companies. Academically she has attended the supervisor course as well as the Post-Graduate Certificate for Higher Education (PGCHE) course. Stephanie helps in the teaching of Immunology and Cancer subject areas and regularly reviews original and review type of papers for journals such as Cancer Immunotherapy, Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and Medicinal Chemistry and Cancer Immunity. Stephanie reviews and writes grants and has been part of many European Grants with Prof. Rees. She has established strong collaborations with national and international laboratories and has organised two ELISPOT workshops in collaboration with C.T. Ltd and overseen an International project involving nine laboratories and presented the results of this study at the European Society of cancer and immunotherapy (ESCII) conference held in Athens, Oct. 2008 and has recently organised a Health and Well-Being conference to bring awareness to cancer sufferers as well as healthy people of ways to improve their immune system. This is an area that Stephanie has started to develop over the last few months in collaboration with Prof. Glenn Gibson, Reading University, expert in Prebiotics. Indeed, she is currently assessing the effect of diet supplementation on vaccine-induced immune responses.

Steve Doberstein

Chief Scientific Officer, Nektar Therapeutics Inc
Steve Doberstein

Steve Doberstein joined Nektar in January 2010 as Senior Vice President and Chief Scientific Officer to lead discovery research at Nektar. Dr. Doberstein brings over 20 years of experience in biotechnology research and development to the company. Prior to joining Nektar, Dr. Doberstein served as Vice President of Research at XOMA, Five Prime Therapeutics, and Xencor, and held a variety of senior positions at Exelixis. His experience spans small molecule, protein therapeutics, and monoclonal antibody discovery and development in therapeutic areas including oncology, neuroscience, inflammation, immunology, and metabolic diseases. Dr. Doberstein also serves as the Chairman of the Board of Nektar India.
Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine where he studied in the laboratory of Dr. Thomas Pollard, and completed his postdoctoral work in Dr. Corey Goodman's laboratory at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.

Sune Justesen

CSO, Immunitrack Aps
Sune Justesen

Sune Justesen has a Ph.D. from the University of Copenhagen. For more than a decade he was responsible for maintaining and developing the probably largest recombinant MHC platform in the laboratory of Dr. Søren Buus. The molecules where used in sensitive peptide binding assays to generate data, that where subsequently used to develop best in class prediction tools for assessing peptide binding to MHC molecules (NetMHC and others). These predictors have proven as invaluable tools in the field of immunology.

 
The know-how and technology was recently spun out into the company Immunitrack, where Dr. Justesen serves as CSO.

Zahra Jawad

Group Leader in Discovery Technology, Agenus
Zahra Jawad

Sponsors and Exhibitors

Official Publication

Supporters

Workshops

Biomarkers of immune response
Workshop

Biomarkers of immune response

Copthorne Tara Hotel
26th September 2017
London, United Kingdom

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Sponsors and Exhibitors


Northwest Biotherapeutics

Sponsors and Exhibitors
http://www.nwbio.com/

NW Bio is developing DCVax® dendritic cell-based therapeutic vaccines. The Company’s DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and Phase II trials in combination with checkpoint inhibitor drugs are planned. The Company’s DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers; various Phase II trials are planned.

Media Partners


International Journal of Computational Biology and Drug Design

Official Publication
http://www.inderscience.com/ijcbdd

IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.


International Journal of Cognitive Biometrics

Official Publication
http://www.inderscience.com/ijcb

Cognitive biometrics acquires information from users through collection of one or more biosignals. This relies on the presentation of one or more external or imagined stimuli. The subsequent response(s) are acquired and used for verification and authentication. IJCB addresses all aspects of cognitive biometrics, which aims to extract a unique signature from the user based on the cognitive, affective and conative state of the individual, either alone or more typically in various multi-modal combinations involving conventional and soft biometrics.


Int. J. of Immunological Studies

Official Publication
http://www.inderscience.com/ijis

IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.


International Journal of Medical Engineering and Informatics

Official Publication
http://www.inderscience.com/ijmei

IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.


International Journal of Behavioural and Healthcare Research

Official Publication
http://www.inderscience.com/ijbhr

IJBHR addresses a broad range of original experimental and theoretical papers that deal with behavioural and healthcare concerns. It welcomes high-quality papers from scientists in academic and non-academic organisations as well as business and government worldwide. IJBHR is sponsored by the Business and Economics Society International and the Frontiers in Immunology Research Network.

Media Partners


pharmaphorum

Supporters
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


BioPharm Insight

Supporters
http://www.biopharminsight.com

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


Samedan

Supporters
http://www.samedanltd.com/magazine/13.

International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


PMR

Supporters
http://www.pmrcorporate.com

PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


Pharmiweb

Supporters
http://www.pharmiweb.com

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


Pharmaceutical Technology

Supporters
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


EIN Presswire

Supporters
http://www.einpresswire.com/free

EIN Presswire has a distribution "foot-print" that includes millions of users of our EIN Newsdesk media monitoring services. We also maintain one of the world's leading media directories providing us with up-to-date contacts for media in every country and U.S. state. Further distribution is achieved via RSS, email, partner websites, and social media. We are both a destination (EIN Newsdesk) and a distributor (EIN Presswire) for news. In one place you can distribute your news to the targeted audiences you select and monitor news on that topic published by thousands of worldwide sources. For more information or to try us FREE, please visit www.einpresswire.com/free


CanBiotech

Supporters
http://www.canbiotech.com

CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


Drug Development Technology

Supporters
http://www.drugdevelopment-technology.com

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


BioChem Adda

Supporters
https://www.biochemadda.com/

BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


Copybook - Pharmaceutical

Supporters
http://www.copybook.com/pharmaceutical

Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


CLocate

Supporters
http://www.clocate.com

Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's website and more...


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


Bentham Science

Supporters
http://www.benthamscience.com/

Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


International Pharmaceutical Industry

Supporters
http://www.ipimediaworld.com

IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


Technology Networks

Supporters
http://www.technologynetworks.com

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Select Science

Supporters
http://www.selectscience.net/

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


Mednous

Supporters
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Pharmaceutical-Tech

Supporters
http://www.pharmaceutical-tech.com

In the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers. Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics. With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


Gate2Biotech

Supporters
http://www.gate2biotech.com

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


Pharmavision

Supporters
http://www.pharmavision.co.uk

PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


Farmavita

Supporters
http://www.farmavita.net/

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


Inderscience Publishers

Supporters
http://www.inderscience.com

Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


Drug Target Review

Supporters
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


Biocompare

Supporters
http://www.biocompare.com

Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


ASD MEDIA

Supporters
http://www.asd-network.com

Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
  • Be informed on the latest market developments; www.asd-network.com
  • Find the latest business news; www.asd-network.com
  • Find the upcoming events; www.asd-network.com
  • Find companies and organizations; www.asdsource.com
  • Distribute news globally. www.asdwire.com
The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

For more detailed information please contact with: ASD MEDIA
Stefan.koopman@asdmedia.nl


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.